Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Arformoterol and Tiotropium in COPD
NCT00424528Phase 4Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of arformoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Time-normalized Area Under the Change From Study Baseline Curve for Forced Expiratory Volume in One Second Over 24 Hours at 2 weeks. Started Dec 2006; status: completed.
02
Drugs
arformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00424528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424528.